Crossmark Global Holdings Inc. Increases Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

Crossmark Global Holdings Inc. increased its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 36.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,020 shares of the company’s stock after purchasing an additional 10,217 shares during the period. Crossmark Global Holdings Inc. owned approximately 0.08% of Immunocore worth $1,121,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. raised its stake in Immunocore by 125.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock valued at $1,463,000 after buying an additional 27,598 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after acquiring an additional 109,206 shares during the period. Pier Capital LLC increased its position in Immunocore by 1.4% during the third quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock valued at $2,568,000 after acquiring an additional 1,174 shares during the last quarter. XTX Topco Ltd lifted its holdings in Immunocore by 72.9% in the third quarter. XTX Topco Ltd now owns 15,459 shares of the company’s stock valued at $481,000 after acquiring an additional 6,516 shares during the period. Finally, Wellington Management Group LLP boosted its position in Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after purchasing an additional 668,382 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price target on shares of Immunocore in a research report on Friday, January 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Thursday, October 24th. Mizuho lowered Immunocore from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Finally, UBS Group assumed coverage on Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Stock Up 0.9 %

NASDAQ IMCR opened at $33.00 on Friday. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 12 month low of $27.69 and a 12 month high of $76.98. The stock’s 50 day moving average is $30.53 and its 200 day moving average is $33.40. The stock has a market cap of $1.65 billion, a PE ratio of -34.74 and a beta of 0.76.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The firm had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. Immunocore’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.59) earnings per share. Research analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.